Myeloproliferative Neoplasm (MPN) Bone Marrow Mononuclear Cells
About:Myeloproliferative Neoplasm (MPN) Bone Marrow Mononuclear Cells - cryopreserved BMMCs isolated from clinically confirmed MPN donors. Marrow morphology and fibrosis grading are central to WHO diagnostic criteria distinguishing polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Ideal for JAK2/CALR/MPL mutation studies. Stratification by MPN subtype and driver mutation status.
About Myeloproliferative Neoplasm (MPN) Bone Marrow Mononuclear Cells
Myeloproliferative Neoplasm (MPN) Bone Marrow Mononuclear Cells for Hematology Research
Myeloproliferative neoplasm (MPN) bone marrow mononuclear cells (BMMCs) are isolated by density-gradient separation from bone marrow aspirate, capturing the full spectrum of marrow-resident hematopoietic stem, progenitor, and precursor cells that peripheral blood samples do not contain. Samples come from consented donors under IRB-approved protocols, each clinically diagnosed with an MPN — a group of clonal hematopoietic stem cell disorders driving overproduction of mature blood cells.
MPN Biology and Why Bone Marrow
- Myeloproliferative neoplasms – including polycythemia vera, essential thrombocythemia, and primary myelofibrosis – arise from clonal hematopoietic stem cells within the bone marrow.
- Marrow morphology, including cellularity, megakaryocyte atypia, and reticulin/collagen fibrosis grading, is central to WHO diagnostic criteria and to distinguishing between MPN subtypes, information that peripheral blood alone cannot provide.
- Driver mutations in JAK2, CALR, or MPL are present in the great majority of MPN cases and are assessed alongside marrow morphology for diagnosis and prognostication.
- JAK inhibitor therapy (e.g. ruxolitinib) has become central to MPN management, and marrow-derived material supports pharmacodynamic and resistance research.
- Marrow fibrosis progression and stem cell clonal dynamics are active areas of research into disease evolution and transformation risk.
Donor Stratification Available
- MPN subtype: polycythemia vera, essential thrombocythemia, or primary myelofibrosis
- Driver mutation status: JAK2, CALR, or MPL
- Marrow fibrosis grade where documented
- Treatment history, including JAK inhibitor exposure
- Age band and sex assigned at birth
- Matched healthy bone marrow controls available
Product Features
- Isolated from clinically confirmed MPN donor bone marrow aspirate
- Density-gradient purified and cryopreserved
- Research Use Only (RUO)
- IRB-approved protocols with documented consent
- Standard and custom cell quantities available
De-identified Donor Data
- MPN diagnosis confirmation, subtype, and driver mutation status where documented
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy and infectious disease history
- Treatment history where documented
- Additional MPN-specific metadata available on request
Applications
- JAK2, CALR, and MPL driver mutation studies
- JAK inhibitor pharmacodynamic and resistance research
- Marrow fibrosis progression and stem cell clonal dynamics studies
- MPN subtype classification and biomarker research
- Disease transformation risk studies
Other Specimen Types
For matched marrow-derived material across conditions, see our human bone marrow mononuclear cells collection, and our myelofibrosis BMMCs for fibrosis-specific studies.
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
MPN BMMCs are available in standard and custom cell quantities. For pricing, international orders, or documentation requirements, please contact our team to confirm compatibility with your country’s regulations.
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Bone Marrow Mononuclear Cells are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Need a custom Bone Marrow Mononuclear Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.